



Oncnostics presents new clinical data on GynTect® Precision Dx for triage of unclear cervical cancer screening tests

Oncnostics is presenting corresponding new clinical data in five presentations at EUROGIN from Dec 4, 2019 to Dec 7, 2019 in Monaco (France).

JENA , GERMANY, December 3, 2019 /EINPresswire.com/ -- Oncnostics GmbH, a Jena/Germany based company, has developed GynTect® for precision detection of cervical cancer. GynTect® was tested and validated in clinical trials on more than 3,000 samples with a remarkable detection score of 100% in all cervical cancer cases. Moreover, GynTect® identifies all relevant pre-cancerous lesions due to its first-of-a-kind prognostic value.

“

Clinical experts have been extremely confident about the validity of our marker panel and the correlation with histopathology findings.”

*Dr. Alfred Hansel, Oncnostics
Chief Executive Officer.*

“Our extended studies have confirmed DNA methylation is an early and frequent event in cervical carcinogenesis. Clinical experts have been extremely confident about the validity of our marker panel and the correlation with

histopathology findings. This offers significant potential to improve cervical cancer screening systems and we are happy to present them in 4 talks at the leading Eurogin conference in Monaco next week”, states Dr. Alfred Hansel, Oncnostics Chief Executive Officer.

Prof. Dr. Matthias Dürst, professor at Jena University Hospital and scientific-cofounder of Oncnostics, will present a comparison of cervical screening triage approaches as invited speakers in a panel discussion.

Together with CSO Dr. Martina Schmitz and two Oncnostics R&D specialists for cervical cancer and head-and-neck cancer diagnostics, Oncnostics will discuss the new clinical data with gynecological Key Opinion Leaders at Oncnostics booth for precision cancer diagnostics.

Ocnostics technology has been exclusively licensed out in 2017 to Sinopharm Group for the greater China region. Biotech Alliances International Inc., a Silicon Valley-based healthcare-focused investment bank, is serving as the lead investment banker to Oncnostics globalization and partnering strategy. Meetings with Oncnostics Management Team can be coordinated at Eurogin 2019 or JP Morgan Conference 2020.

Franck Brinkhaus
Biotech Alliances International INC
+1 650-868-8511
[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2020 IPD Group, Inc. All Right Reserved.